Mirtazapine augmentation in treatment-resistant major depressive disorder: an open-label, six-week trial

被引：0
|
作者：
Aydemir, O [1 ]
Taskin, EO [1 ]
Deveci, A [1 ]
机构：
[1] Celal Bayar Univ Hosp, Manisa, Turkey
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2005年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S401 / S402
页数：2
相关论文
共 50 条
  • [41] An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder
    Grant, Paul
    Lougee, Lorraine
    Hirschtritt, Matthew
    Swedo, Susan E.
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2007, 17 (06) : 761 - 767
  • [42] Ziprasidone in treatment-resistant schizophrenia: A 52-week, open-label continuation study
    Loebel, Antony D.
    Khanna, Surnant
    Rajadhyaksha, Sunita
    Siu, Cynthia O.
    Giller, Earl
    Potkin, Steven G.
    JOURNAL OF CLINICAL PSYCHIATRY, 2007, 68 (09) : 1333 - 1338
  • [43] Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder
    Papakostas, GI
    Petersen, TJ
    Kinrys, G
    Burns, AM
    Worthington, JJ
    Alpert, JE
    Fava, M
    Nierenberg, AA
    JOURNAL OF CLINICAL PSYCHIATRY, 2005, 66 (10) : 1326 - 1330
  • [44] A randomized open-label trial of paroxetine versus paroxetine plus sulpiride in the treatment of major depressive disorder
    Uchida, H
    Takeuchi, H
    Nomura, K
    Suzuki, T
    Watanabe, K
    Kashima, H
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2005, 20 (03) : A16 - A16
  • [45] Low and high dose aripiprazole augmentation in major depressive disorder: a randomised, open-label study
    Horikoshi, S. H.
    Miura, I. M.
    Yamamoto, S. Y.
    Abe, O. A.
    Ito, M. I.
    Watanabe, K. W.
    Nozaki, K. N.
    Kaneko, H. K.
    Yabe, H. Y.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S861 - S861
  • [46] Mirtazapine in Comorbid Major Depression and Alcohol Dependence: An Open-Label Trial
    Cornelius, Jack R.
    Douaihy, Antoine B.
    Clark, Duncan B.
    Chung, Tammy
    Wood, D. Scott
    Daley, Dennis
    JOURNAL OF DUAL DIAGNOSIS, 2012, 8 (03) : 200 - 204
  • [47] Olanzapine in Chinese treatment-resistant patients with schizophrenia: An open-label, prospective trial
    Chiu, NY
    Yang, YK
    Chen, PS
    Chang, CC
    Lee, IH
    Lee, JR
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2003, 57 (05) : 478 - 484
  • [48] Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes A Nonrandomized Open-Label Trial
    Aaronson, Scott T.
    van der Vaart, Andrew
    Miller, Tammy
    LaPratt, Jeffrey
    Swartz, Kimberly
    Shoultz, Audrey
    Lauterbach, Margo
    Sackeim, Harold A.
    Suppes, Trisha
    JAMA PSYCHIATRY, 2024, 81 (06) : 555 - 562
  • [49] Cannabidiol for Treatment-Resistant Anxiety Disorders in Young People: An Open-Label Trial
    Berger, Maximus
    Li, Emily
    Rice, Simon
    Davey, Christopher G.
    Ratheesh, Aswin
    Adams, Sophie
    Jackson, Henry
    Hetrick, Sarah
    Parker, Alexandra
    Spelman, Tim
    Kevin, Richard
    McGregor, Iain S.
    McGorry, Patrick
    Amminger, G. Paul
    JOURNAL OF CLINICAL PSYCHIATRY, 2022, 83 (05)
  • [50] Efficacy and Tolerability of Generic Mirtazapine (Mirtax) for Major Depressive Disorder: Multicenter, Open-label, Uncontrolled, Prospective Study
    Song, Hoo Rim
    Bahk, Won-Myong
    Woo, Young Sup
    Jeong, Jong-Hyun
    Kwon, Young-Joon
    Seo, Jeong Seok
    Kim, Won
    Kim, Moon-Doo
    Shin, Young-Chul
    Lee, Sang-Yeol
    Min, Kyung Joon
    CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2015, 13 (02) : 144 - 149
12345